Navigation Links
Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
Date:1/3/2008

KENILWORTH, N.J., Jan. 3 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that its Board had elected Dr. Craig B. Thompson as a member of its Board of Directors, effective Jan. 2, 2008. Dr. Thompson is Director of the Abramson Cancer Center and Professor of Medicine at the University of Pennsylvania School of Medicine in Philadelphia.

Dr. Thompson is an independent director under both the New York Stock Exchange standards and the more restrictive Schering-Plough Board independence standards.

Dr. Thompson, 54, earned an M.D. from the University of Pennsylvania School of Medicine and an AB from Dartmouth College. He chairs the Medical Advisory Board at the Howard Hughes Medical Institute, serves on the advisory boards of St. Jude Children's Research Hospital and M.D. Anderson Cancer Center, and participates in a number of other professional and civic activities.

"Craig's perspective as a scientist and physician will add significant strength to our work as a Board," said Patricia F. Russo, Chair of the Board's Nominating and Corporate Governance Committee. "We are pleased to continue to increase the collective knowledge of the Board with this new member."

"Craig brings deep experience to our Board in the fields of medicine, medical research and fighting cancer, an important priority for humankind. This additional strength on the Board is critical as we continue to increase Schering-Plough's science-focus during our progression along our Action Agenda to transform Schering-Plough into a high-performance, global competitor for the long term," said Fred Hassan, Schering-Plough chairman and chief executive officer.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. In November 2007, Schering-Plough acquired Organon BioSciences, with its Organon human health and Intervet animal health businesses, marking a pivotal step in the company's ongoing transformation. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its approximately 50,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
2. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
3. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
4. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
7. Schering-Plough Reports Financial Results for Third Quarter of 2007
8. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Louise McCormick Joins Heskas Board of Directors
11. Combined Boards Provide Better Care to More Clients More Efficiently
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 31, 2016 , ... The University of Tennessee Medical Center ... the latest in Clinical Patient Pod (CPP) technologies provided through Jvion’s ... into the clinical workflow. These insights are empowering the more than 30 case ...
(Date:5/31/2016)... Calif. (PRWEB) , ... May 31, 2016 , ... Effective ... colleagues, clients, and the industry as a whole. On June 2, Northbound CEO Mike ... on Addictive Disorders (WCSAD) and presenting the opening plenary on “Leadership: The Journey to ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... planetary and numeral energies can describe personality traits in humans. Using presidential candidate ... behind their name and vitality. , “AstroNumerology is not about adding numbers ...
(Date:5/31/2016)... ... ... TeaZa® Energy, LLC announces the launch of a new limited ... . The new flavor—Tropical TeaZa? Energy—will be available to customers exclusively online starting ... flavor is best described as a juicy, taste bud takeover. A mouthwatering wave ...
(Date:5/31/2016)... ... May 31, 2016 , ... To ... solutions to the healthcare industry, The University of Scranton is adding a Certificate ... path to a career in rapidly growing field of healthcare information. , ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... -- Since its commercial introduction in 2005, ... science tool for conducting genetic studies in a range ... its new report that the industry sits on the ... a range of new applications in the clinical diagnostics ... ) , Since the Human Genome ...
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
Breaking Medicine Technology: